ClinicalTrials.gg
CompletedNCT00857935Updated Mar 9, 2009

A Safety and Efficacy Pilot Study Comparing NatrOVA Creme Rinse 1% and NIX Creme Rinse

A Phase 2 interventional study of NatrOVA Creme Rinse - 1% and NIX Creme Rinse - 1% permethrin in Pediculosis Capitis and Head Lice, sponsored by ParaPRO LLC. Completed at 1 site in United States. Open to participants aged 6 Months and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2009-03-09.

Sponsored by ParaPRO LLC · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
6 Months and older
Sex
All
01

Study summary

A pilot study to compare the safety and efficacy of NatrOVA Creme Rinse 1% to NIX Creme Rinse in subjects with Pediculosis Capitis

Read the detailed description

A Phase 2b, randomized, single-site, investigator/evaluator blind, two-arm, parallel-group pilot study that tested the operational elements of an "Actual Use" study designed to evaluate the safety and efficacy of a 10-minute treatment and no-nit combing regimen of NatrOVA Creme Rinse 1% versus NIX Creme Rinse in subjects with at least a mild case of head lice.

02

Conditions studied

  • Pediculosis Capitis
  • Head Lice

Browse trials for

Keywords

  • Pediculosis Capitis
  • Head Lice
03

In context

Lice Infestations

43 studies on the registry are indexed under Lice Infestations; 4 are open to participants now.

This study's enrollment of 24 is below the median of 105 across 42 interventional studies indexed under Lice Infestations.

Browse Lice Infestations studies →

Lead sponsor

ParaPRO LLC is the lead sponsor of 11 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, 6 months of age or older
  • Subject must have a head lice infestation present at baseline
  • Subject/caregiver must read English or Spanish at a 7th grade level
  • Subject must have an appropriately signed agreement
  • Other members of the household with a lice infestation must be willing to be enrolled in the study or treat their infestations with a standard treatment
  • Subject agreement to not use any other form of lice treatment during the course of the study
  • Subject agreement to not cut or chemically treat their hair in the period between baseline and final, post-treatment visits

Exclusion criteria

Exclusion Criteria:

  • Individuals with a history of irritation or sensitivity to pediculicides or hair care products
  • Individuals with any visible skin/scalp condition at the treatment site that could interfere with the evaluation
  • Individuals previously treated with a pediculicide or any other head lice treatment product within 48 hours prior to enrollment
  • Individuals receiving systemic or topical drugs that may interfere with the study results
  • Individuals who have participated in a clinical trial within 30 days of enrollment
  • Individuals with family members who are infested with lice but are unwilling or unable to enroll in the study or to use the standard course of lice treatment
  • Females who are pregnant or nursing
  • Sexually-active females not using effective
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    1

    NatrOVA Creme Rinse - 1%

    Drug: NatrOVA Creme Rinse - 1%

  • Active comparator
    2

    NIX Creme Rinse

    Drug: NIX Creme Rinse - 1% permethrin

Interventions

  • DrugNatrOVA Creme Rinse - 1%

    NatrOVA Creme Rinse, one or two, 10-minute topical treatments (7 days apart)

  • DrugNIX Creme Rinse - 1% permethrin

    NIX Creme Rinse: one or two, 10-minute topical treatments (7 days apart)

06

What researchers measure

Primary outcomes

  1. Efficacy of NatrOVA Creme Rinse-1% versus NIX Creme rinse, based on the presence or absence of live lice 14 days after the final treatment.

    Time frame: 14 days after last treatment

Secondary outcomes

  1. Safety comparison between NatrOVA Creme Rinse-1% and NIX Creme Rinse, based on the occurrence of adverse events and any increase of scalp and/or ocular irritation, post-treatment.

    Time frame: 14 days after last treatment

07

Study locations

1 site
  • Concentrics Research
    Indianapolis, Indiana 46240, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 9, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00857935
Lead sponsor
ParaPRO LLC
First posted
Mar 9, 2009
Start date
Mar 2007
Primary completion
Apr 2007
Completion
Apr 2007
Last update
Mar 9, 2009

Study contacts

Mark Moore, MD
principal investigator · Concentrics Research

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion